ShengDa Bio-Pharm
ShengDa Bio-Pharm, also known as ShengDa Pharmaceutical, is a prominent player in the biopharmaceutical industry, headquartered in China (CN). Established in 2001, the company has made significant strides in the development and manufacturing of innovative pharmaceutical products, particularly in the fields of oncology and infectious diseases. With a strong operational presence across Asia and expanding into global markets, ShengDa Bio-Pharm is recognised for its commitment to research and development. The company’s core offerings include a range of high-quality biopharmaceuticals that leverage advanced technologies, setting them apart in a competitive landscape. Notably, ShengDa Bio-Pharm has achieved several key milestones, including successful clinical trials and partnerships that enhance its market position. As a result, the company continues to be a trusted name in the biopharmaceutical sector, dedicated to improving patient outcomes worldwide.
DitchCarbon Score
How does ShengDa Bio-Pharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ShengDa Bio-Pharm's score of 25 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ShengDa Bio-Pharm's reported carbon emissions
In 2023, ShengDa Bio-Pharm reported total carbon emissions of approximately 69,261,580 kg CO2e, with Scope 1 emissions at about 23,017,480 kg CO2e and Scope 2 emissions at around 46,244,100 kg CO2e. This represents a decrease from 2022, where total emissions were approximately 87,409,670 kg CO2e, with Scope 1 at about 38,174,740 kg CO2e and Scope 2 at approximately 49,234,930 kg CO2e. The company has shown a notable reduction in emissions from 2022 to 2023, with a total decrease of about 18,148,090 kg CO2e. In 2021, their total emissions were approximately 71,917,720 kg CO2e, indicating a positive trend in their emissions management. Despite these reductions, ShengDa Bio-Pharm has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on improving its emissions intensity, which was reported at approximately 5,120 kg CO2e per tonne of output in 2023. Overall, ShengDa Bio-Pharm's commitment to reducing carbon emissions is evident through their recent performance, although further transparency regarding specific climate commitments would enhance their sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 38,113,500 | 00,000,000 | 00,000,000 |
| Scope 2 | 33,804,220 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ShengDa Bio-Pharm is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
